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than 10 is signiﬁcant PH above which the complications
like variceal bleed and ascites develop. Currently proposed
classiﬁcation of cirrhosis is based on the degree of PH
and associated clinical features. Development of ascites,
variceal bleed and hepatic encephalopathy is considered
to be decompensated cirrhosis. PH results from increase
in the intrahepatic resistance which has dynamic and ﬁxed
components and it is coupled with increase in the portal
blood ﬂow. Therapeutic interventions which can reduce the
HVPG like non selective beta blockers and Transjugular
intrahepatic porta systemic shunt (TIPS) can be helpful in
combating complications of cirrhosis. And they have been
shown to improve survival. Bacterial infection is common in
cirrhosis with one month mortality of 30%. Oral prophylactic
antibiotics or bowel decontamination have shown to
improve long term outcome in patients with decompensated
cirrhosis. Malnutrition is common in all patients with
cirrhosis. Now it is clear there is no need of restricting
the proteins in these patients. In fact nutritional therapy
can improve survival, reduce the rate of infections, stay in
ICU and hospital, and reduce post operative complications.
Screening for hepatocellular carcinoma (HCC) can pick up
very early disease and survival can be improved in these
patients by offering curative treatment. Therapeutic modal-
ities can reverse the cirrhosis. These modalities according
to the etiology are (1) abstinence for alcoholic cirrhosis,
(2) antiviral therapy for hepatitis B, (3) immunosuppression
for autoimmune hepatitis, (4) relieving biliary obstruction
in patients with secondary biliary cirrhosis, (5) antiviral
therapy for hepatitis C and (6) relieving obstruction in
patients with budd Chiari syndrome. Future therapies like
antiﬁbortic, antiangiogenic and anti coagulants may have
potentials reducing ﬁbrosis, reversing cirrhosis. Stem cell
therapy may be helpful in patients with liver cirrhosis.
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PL-001 USP18 stimulates HCV production in vitro:
a novel mechanism for HCV resistance to
interferon therapy
L.M. Chen1 *, J. Sun1, L.-T. Lin2, M.X. Ma1, C. Richardson2,
A. Edwards1, J. Feld1, I. McGilvray1. 1University of Toronto,
2Dalhousie University, Canada
Background: The molecular mechanisms of interferon
resistance in almost 50% of the HCV infected patients remain
unclear. We have previously identiﬁed that upregulation
of interferon stimulated genes (ISGs), such as Interferon
Stimulated Gene15 (ISG15) and Ubiquitin Speciﬁc Protease
18 (USP18) in hepatocytes, predicts treatment failure.
Moreover, silencing USP18 potentiates IFN anti-HCV activity
and increased expression of ISG15 promotes HCV production.
In this study we investigate the role of USP18 in HCV
production.
Methods: We studied the effect of over-expression of
wild type (catalytically active) USP18 or an enzymatically
inactive mutant form of USP18 on HCV RNA replication and
viral production in JFH1 culture system. Levels of various
ISGs and of the critical miRNA 122 were assessed by real-
time PCR, and surface expression of the key HCV entry
receptor, CD81, were quantiﬁed by FACS.
Results: Over-expression of wild type and mutant USP18
increases HCV production at baseline (without IFN) and
blunts the anti-HCV activity of IFNa in the JFH1 infectious
system. While neither ISG expression nor miRNA 122 levels
were unaffected by overexpression of USP18, whether in the
presence or absence of IFNa, surface expression of CD81 was
increased following USP18 over-expression in Huh7.5 cells.
Conclusions: These data indicate that USP18 overexpression
leads to increased HCV production independent of its
catalytic activity, and in concert with increased surface
expression of CD81. Thus, USP18, one of the ISGs increased
in chronic HCV infection, stimulates HCV production and
likely contributes to treatment failure by promoting HCV
cell entry and blunting IFN anti-HCV activity.
OL-001 Clinico-epidemiological proﬁle of patients with
hepatitis C virus infection seen in private
practice clinics in Metro Manila
R. Forroza1 *, E. Labio1, V. Banez1, J. Ong1. 1Philippine
General Hospital, Philippines
Background: Hepatitis C virus (HCV) infection is a major
public health problem worldwide. In the Philippines, there
are few published data on the clinico-epidemiological proﬁle
of patients with HCV infection.
Methodology: Out-patient charts of patients seen from
October 2005 to November 2010 in private practice clinics of
3 gastroenterologists were reviewed. All patients with a pos-
itive anti-HCV and/or HCV-RNA were included. Clinical and
epidemiologic information were collected and analyzed.
Results: Of 49 patients included, 27 (55%) were males.
Mean age at diagnosis was 48.5 years. 26 patients had HCV
genotype data genotype 1 in 16 (61%) patients, genotype
2 in 8 (31%), genotype 4 in 2 (8%). The most common
risk factor was blood transfusion before 1990 identiﬁed in
18 (37%) patients. Other risk factors identiﬁed: injection
drug use (IDU) 7 (14%), hemodialysis (HD) 7 (14%), unknown
11 (23%), others 5 (12%). At presentation, 17 (35%) patients
had advanced HCV-related liver disease 13 cirrhosis only
and 4 hepatocellular carcinoma (HCC). Among 37 evaluable
treatment-naïve patients, 16 (43%) were ineligible for
treatment with advanced HCV-related liver disease (69%)
as the most common reason.
Conclusion: In this study, blood transfusion before 1990,
IDU, and HD were the most common risk factors for
HCV infection. Many patients had advanced liver disease
precluding eligibility for therapy. Screening for HCV among
those with a history of blood transfusion before 1990,
IDU, and HD may help identify HCV-infected patients
early allowing institution of antiviral therapy to prevent
progressive liver disease.
OL-002 Could faluvastatin affect the sustained
virological response in chronic hepatitis C virus
treatment?
M. El-Hamamsy1 *, M. Azmy2, G. Badr2, M. Houssein2.
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Background: Hepatitis C viral (HCV) infection is the leading
cause of death due to liver disease. Additional agents are
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needed to increase the cure rate. In vitro experiments show
strong antiviral effects of ﬂuvastatin against HCV.
Aim of the study: To asses the clinical outcome of ﬂuvastatin
addition to the standard regimen for treatment of chronic
HCV in Egypt.
Subjects and Methods: The study included 80 patients
with chronic hepatitis C virus infection fulﬁlled clinical,
laboratory and histo-pathological criteria to be ready for
interferon therapy, divided into two groups: Group I (n = 40)
received standard treatment for HCV (pegylated interferon
and ribavirin) and group II (n = 40) received standard
treatment plus ﬂuvastatin (80mg/daily). Before and after
6 months of treatment liver function tests and HCV-RNA
were evaluated.
Results: Addition of ﬂuvastatin to the standard HCV
treatment (pegylated interferon and ribavirin) signiﬁcantly
increased SVR from (55% to 62.5%; P< 0.01) and signiﬁcantly
decreased viral load in relapser patients (P< 0.001). No
signiﬁcant differences and correlations were found between
serum levels of LDL-cholesterol and viral load before and
after treatment in both groups.
Conclusion: Fluvastatin can be used to increase SVR when
added to standard treatment (pegylated interferon and
ribavirin) of chronic HCV.
OL-003 Genetic changes in the interferon sensitivity
determining region of hepatitis C virus during
the natural course of chronic hepatitis C 3a may
lead to non-response to interferon therapy
A. Raza1 *, J. Asad2, N. Zaman2, H. Aziz1, S. Murtaza1,
J. Irfan1. 1Nuclear Medicines Oncology and Radiotherapy
Institute, 2PMAS Arid Agriculture University Rawalpindi,
Pakistan
Background: We have found 70% response rate in Pakistan
for Genotype-3a patients with combinationtherapy of
interferon and ribavirin. There is need to individualize the
treatment to minimize the side effects.
Methods: For the current study ﬁve G3 patients,
nonresponder of 24 weeks interferon-alpha-2b plus ribivirin
therapy, withalmost equal levels of viremia (1.8×107
IU/ml) at the end of treatmentwere selected. Mean
viral load at week 36 was 2.6×106 IU/ml, atweek 48
raised to 2.0×107 IU/ml. All samples were quantiﬁed on
RotorGene3000™. Interferon sensitivity-determining region
(ISDR) innon-structural region-5A was studied to link any
genetic changes in virus genomewith therapy esistance.
ISDR was ampliﬁed using genotype 3aspeciﬁc ISDR primers
followed by sequencing and bioinformatics tools.
Result: A157bp ISDR product corresponding to 52 aminoacid
protein, when compared with responderHCV patient naïve
genome [Table 1], eight amino acid mutations were
detected includingdeletions and substitutions affecting the
molecular weight of protein. Gly, Trp, Pro, Leu. His,
Thr were substituted by Arg, Gln, Ala, Pro, Pro, Ala
respectively.
Conclusion: Mutations in ISDR region may have role in
virus-resistance and high viremia, inﬂuencingthe therapy
response. Screening will help in deciding treatment plan
makingit cost-effective.
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L. Zhang1 *, C. Qin2, Y. An1, X. Zhang1, L. Wang3.
1Department of liver Diseases, Jinan Infectious Disease
Hospital afﬁliated to Shandong University, Jinan, Shandong
province, 250021, PR China, 2Department of Digestive
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Objectives: Our aim was to identify the prevalence of
hepatitis C virus (HCV) genotype and investigate genetic
mutation of HCV 5′ non-coding region (5′NCR) sequences in
Shandong province of China.
Methods: Serum samples from 118 chronic hepatitis C
patients hospitalized in Jinan Infectious Disease hospital
were collected. Serum samples were ampliﬁed from 5′NCR
by RT-PCR and PCR products were sequenced by Sangon
Biotech (Shanghai) Co., Ltd. Sequences of 5′NCR of the
patients were compared with reference HCV strains from
Genebank and phylogenetic tree analysis was performed.
Results: The cases among genotype 1b, 2a, 1a, 3a, 3b, 6a
were 65 (55.1%), 45 (38.1%), 2, 1, 2 and 3, respectively.
Sequences of 5′NCR in 42 genotype 1b patients were
identical. Compared to reference HCV 1b strains, 23
genotype 1b patients have 1 2 bases mutation with two
characteristic nucleotide mutation sites (120 C-T and 204
C-T). The homology of 5′NCR among genotype 2a patients
was 97.8%-100% with characteristic nucleotide mutation
sites (site 222 C-T and 247 C-T). The homology of genotype
1a, 3a, 3b and 6a with the same genotype HCV stains from
Genebank was high, only with 1 3 bases mutation.
Conclusions: The predominant genotype of chronic
hepatitis C patients in Shandong province is 1b, followed
by 2a and a small amount of 1a, 3a, 3b, 6a. Genotype 3a
and 6a are not reported before. Sequence of HCV 5′NCR is
highly conservative and accords to HCV strains worldwide.
Both genotype 1b and 2a have characteristic nucleotide
mutations.
OL-005 A higher correlation of HCV core antigen with
CD4+ T cell counts in HCV/HIV coinfected
patients
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1Infection Disease Center & Department of Microbiology,
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Background: Development of HCV infection is typically
followed by chronic hepatitis C (CHC) in most patients,
while spontaneous HCV viral clearance (SVC) occurs in only
a minority of subjects. With the development of techniques
for direct detection of the HCV virus (RNA or core protein), it
is expected that HCV infectious status can be evaluated bet-
ter if the results of HCV antibodies and virus detection were
